Peptidomics analysis of human blood specimens for biomarker of discovery

Expert Review of Molecular Diagnostics

Volumn 7, Issue 5, 2007, Pages 605-613

  Tammen, Harald ^a   Peck, Andrew ^b   Budde, Petra ^a   Zucht, Hans Dieter ^a  

^a Digilab BioVisioN GmbH   (Germany)

^b Digilab Inc   (United States)

Author keywords

Biomarker; Inhibition; Mass spectrometry; Peptide; Peptidomics; Protease; Proteomics; Validation

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 19; DIPEPTIDYL PEPTIDASE IV; PEPTIDE; PROCALCITONIN; PROINSULIN; PROTEINASE; PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD SAMPLING; ENZYME INHIBITION; HUMAN; IN VIVO STUDY; MASS SPECTROMETER; MEDICAL RESEARCH; PEPTIDE ANALYSIS; PEPTIDOMICS; PROTEIN STRUCTURE; REVIEW; SENSITIVITY AND SPECIFICITY; BLOOD; MASS SPECTROMETRY; PROTEOMICS;

BIOLOGICAL MARKERS; HUMANS; MASS SPECTROMETRY; PEPTIDES; PROTEOMICS;

EID: 35148835538     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.5.605     Document Type: Review

References (73)

1. Schrader M, Schulz-Knappe P. Peptidomics technologies for human body fluids. Trends Biotechnol. 19(10 Suppl.), 55-60 (2001).
2. Baggerman G, Verleyen P, Clynen E, Huybrechts J, de Loof A, Schoofs L. Peptidomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 803(1), 3-16 (2004).
3. Soloviev M, Finch P. Peptidomics, current status. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 815(1-2), 11-24 (2005).
4. Tammen H, Zucht HD, Budde P. Oncopeptidomics - a commentary on opportunities and limitations. Cancer Lett. 249(1), 80-86 (2007).
5. Schulz-Knappe P, Zucht HD, Heine G, Jurgens M, Hess R, Schrader M. Peptidomics: the comprehensive analysis of peptides in complex biological mixtures. Comb. Chem. High Throughput Screen. 4(2), 207-217 (2001).
6. Pierson J, Norris JL, Aerni HR, Svenningsson P, Caprioli RM, Andren PE. Molecular profiling of experimental Parkinson's disease: direct analysis of peptides & proteins on brain tissue sections by MALDI mass spectrometry. J. Proteome Res. 3(2), 289-295 (2004).
7. Pasinetti GM, Ungar LH, Lange DJ et al. Identification of potential CSF biomarkers in ALS. Neurology 66(8), 1218-1222 (2006).
8. Sasaki K, Sato K, Akiyama Y, Yanagihara K, Oka M, Yamaguchi K. Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. Cancer Res. 62(17), 4894-4898 (2002).
9. Zhang X, Wei D, Yap Y, Li L, Guo S, Chen F. Mass spectrometry-based 'omics' technologies in cancer diagnostics. Mass. Spectrom. Rev. 26(3), 403-431 (2007). • Describes mass spectrometry (MS)-based multiplex methods for the measurement of analytes in various biological sources and expands the view beyond peptidomics.
10. Lopez MF, Mikulskis A, Kuzdzal S et al. A novel, high-throughput workflow for discovery and identificapeptide biomarker candidates in ovarian cancer samples. Clin. Chem. 53(6), 1067-1074 (2007). • Describes the identification of albumin-bound molecules from serum samples as discriminators between control individuals and ovarian cancer patients.
11. Philip R, Murthy S, Krakover J et al. Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J. Proteome. Res. 6(7), 2509-2517 (2007).
12. Schulte I, Tammen H, Selle H, Schulz-Knappe P. Peptides in body fluids and tissues as markers of disease. Expert Rev. Mol. Diagn. 5(2), 145-157 (2005).
13. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002).
14. Le L, Chi K, Tyldesley S et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin. Chem. 51(4), 695-707 (2005).
15. Ye B, Cramer DW, Skates SJ et al. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 9(8), 2904-2911 (2003).
16. Malik G, Ward MD, Gupta SK et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin. Cancer Res. 11(3), 1073-1085 (2005).
17. Diamandis EP. Oncopeptidomics: a useful approach for cancer diagnosis? Clin. Chem. 53(6), 1004-1006 (2007).
18. de Noo ME, Tollenaar RA, Deelder AM, Bouwman LH. Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears. World J. Gastroenterol. 12(41), 6594-6601 (2006).
19. Schrader M, Selle H. The process chain for peptidomic biomarker discovery. Dis. Markers 22(1-2), 235-245 (2006).
20. Schmitt M, Harbeck N, Daidone MG et al. Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the receptor and biomarker group of the European Organization for Research and Treatment of Cancer. Int. J. Oncol. 25(5), 1397-1406 (2004).
21. Vierhapper H, Niederle B, Bieglmayer C, Kaserer K, Baumgartner-Parzer S. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 15(11), 1267-1272 (2005).
22. Yuan F, Dellian M, Fukumura D et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55(17), 3752-3756 (1995).
23. Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br. J. Cancer 82(9), 1513-1518 (2000).
24. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1(11), 845-867 (2002).
25. Rai AJ, Vitzthum F. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma implications for clinical proteomics. Expert Rev. Proteomics 3(4), 409-426 (2006).
26. Rai AJ, Gelfand CA, Haywood BC et al. HUPO plasma proteome project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5(13), 3262-3277 (2005).
27. Hsieh SY, Chen RK, Pan YH, Lee HL. Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling. Proteomics 6(10), 3189-3198 (2006).
28. Tammen H, Schulte I, Hess R, Menzel C, Kellmann M, Schulz-Knappe P. Prerequisites for peptidomic analysis of blood samples I. Evaluation of blood specimen qualities and determination of technical performance characteristics. Comb. Chem. High Throughput Screen. 8(8), 725-733 (2005).
29. Landi MT, Caporaso N. Sample collection, processing and storage. IARC Sci. Publ. 142, 223-236 (1997).
30. Holland NT, Smith MT, Eskenazi B, Bastaki M. Biological sample collection and processing for molecular epidemiological studies. Mutat. Res. 543(3), 217-234 (2003).
31. Tammen H, Schulte I, Hess R et al. Peptidomic analysis of human blood specimens: comparison between plasma Specimens and serum by differential peptide display. Proteomics 5(13), 3362-3377 (2005).
32. Omenn GS, States DJ, Adamski M et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5(13), 3226-3245 (2005). • Summarizes the results from the Human Proteome Organization (HUPO) plasma pilot studies and gives recommendations for sample handling.
33. Pfeifer PH, Brems JJ, Brunson M, Hugli TE. Plasma C3a and C4a levels in liver transplant recipients: a longitudinal study. Immunopharmacology 46(2), 163-174 (2000).
34. Villar-Garea A, Griese M, Imhof A. Biomarker discovery from body fluids using mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 849(1-2), 105-114 (2007).
35. Aristoteli LP, Molloy MP, Baker MS. Evaluation of endogenous plasma peptide extraction methods for mass spectrometric biomarker discovery. J. Proteome. Res. 6(2), 571-581 (2007).
36. Frode SB, Ann CK, Magnus B et al. Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin. Appl. 1(7), 699-711 (2007).
37. Mehta AI, Ross S, Lowenthal MS et al. Biomarker amplification by serum carrier protein binding. Dis. Markers 19(1), 1-10 (2003).
38. Gong Y, Li X, Yang B et al. Different immunoaffinity fractionation strategies to characterize the human plasma proteome. J. Proteome. Res. 5(6), 1379-1387 (2006).
39. Yan W, Chen SS. Mass spectrometry-based quantitative proteomic profiling: Brief Funct. Genomic. Proteomic 4(1), 27-38 (2005).
40. Chen X, Sun L, Yu Y, Xue Y, Yang P. Amino acid-coded tagging approaches in quantitative proteomics. Exp. Rev. Proteomics 4(1), 25-37 (2007).
41. Villanueva J, Philip J, Entenberg D et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 76(6), 1560-1570 (2004).
42. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun. 292(3), 587-592 (2002).
43. Fenn JB, Mann M, Meng F, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 246(4926), 64-71 (1989).
44. Zucht HD, Lamerz J, Khamenia V et al. Datamining methodology for LC-MALDI-MS based peptide profiling. Comb. Chem. High Throughput Screen. 8(8), 717-723 (2005).
45. Palagi PM, Walther D, Quadroni M et al. MSight: an image analysis software for liquid chromatography-mass spectrometry. Proteomics 5(9), 2381-2384 (2005).
46. Lamerz J, Selle H, Scapozza L et al. Correlation-associated peptide networks of human cerebrospinal fluid. Proteomics 5(11), 2789-2798 (2005).
47. Villanueva J, Martorella AJ, Lawlor K et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics 5(10), 1840-1852 (2006).
48. Semmes OJ, Feng Z, Adam BL et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin. Chem. 51(1), 102-112 (2005).
49. Diamandis EP. Peptidomics for cancer diagnosis: present and future. J. Proteome. Res. 5(9), 2079-2082 (2006). • A critical review on peptidomics and its application to biomarker discovery.
50. Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin. Chem. 51(1), 3-5 (2005). •• Comprehensive overview of applications using MALDI or SELDI to discover probable valid biomarkers. In-depth technical explanations and a synopsis of various biomarker studies, with emphasis on analytical sensitivity.
51. Koomen JM, Shih LN, Coombes KR et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin. Cancer Res. 11(3), 1110-1118 (2005).
52. Davis MT, Patterson SD. Does the serum peptidome reveal hemostatic dysregulation? Ernst. Schering. Res. Found. Workshop 61, 23-44 (2007).
53. Teahan O, Gamble S, Holmes E et al. Impact of analytical bias in metabonomic studies of human blood serum and plasma. Anal. Chem. 78(13), 4307-4318 (2006).
54. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J. Clin. Invest. 116(1), 26-30 (2006).
55. Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116(1), 271-284 (2006).
56. Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Natl Rev. Cancer 6(12), 961-967 (2006).
57. Chambers AF, Vanderhyden BC. Ovarian cancer biomarkers in urine. Clin. Cancer Res. 12(2), 323-327 (2006).
58. Zolg W. The proteomics search for diagnostic biomarkers: lost in translation? Mol. Cell. Proteomics 5(10), 1720-1726 (2006). • Important issues for validating putative biomarkers.
59. Paweletz CP, Wiener MC, Sachs JR et al. Surface enhanced laser desorption ionization spectrometry reveals biomarkers for drug treatment but not dose. Proteomics 6(7), 2101-2107 (2006).
60. Rossi L, Martin BM, Hortin GL et al. Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics 6(2), 709-720 (2006).
61. Walker CC, Salinas KA, Harris PS, Wilkinson SS, Watts JD, Hemmer MJ. A proteomic (SELDI-TOF-MS) approach to estrogen agonist screening. Toxicol. Sci. 95(1), 74-81 (2007).
62. Rawlings ND, Morton FR, Barrett AJ. MEROPS: the peptidase database. Nucleic Acids Res. 34, D270-D272 (2006).
63. Koomen JM, Li D, Xiao LC et al. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J. Proteome. Res. 4(3), 972-981 (2005).
64. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40(3), 209-294 (2003).
65. Yates NA, Deyanova EG, Geissler W et al. Identification of peptidase substrates in human plasma by FTMS based differential mass spectrometry. Int. J. Mass Spectrom. 259(1), 174-183 (2007).
66. Schulte I, Tammen H, Selle H, Zucht HD, Schulz-Knappe P. Clinical peptidomics: peptide-biomarker discovery in blood. In: Proteomics & Peptidomics. Marko-Varga G (Ed.). Elsevier Science, Amsterdam, The Netherlands (2005).
67. Marco J, Budde P, Tammen H, Schulz-Knappe P. Peptidomics based protease inhibitor profiling. In: Peptidomics in Drug Development. Peta Schulz-Knappe (Ed.). Editio Cantor, Aulendorf, Germany (2007).
68. Schrader M, Budde P, Rose H, Lamping N, Schulz-Knappe P, Zucht HD. Peptidomics technologies and applications in drug research. In: Proteomics in Drug Research. Michael Hamacher (Ed.). Wiley London, UK (2007).
69. Phillips KA, Van Bebber S, Issa AM. Diagnostics and biomarker development: priming the pipeline. Nat. Rev. Drug Discov. 5(6), 463-469 (2006).
70. Paradis V, Degos F, Dargere D et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41(1), 40-47 (2005).
71. Ward DG, Cheng Y, N'Kontchou G et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br. J. Cancer 94(2), 287-292 (2006).
72. Gobel T, Vorderwulbecke S, Hauck K, Fey H, Haussinger D, Erhardt A. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J. Gastroenterol. 12(47), 7604-7612 (2006).
73. Lee IN, Chen CH, Sheu JC et al. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 6(9), 2865-2873 (2006).